- 1 Hypothesis-free detection of gene-interaction effects on
- 2 biomarker concentration in UK Biobank using variance
- 3 prioritisation

7

- 5 Matthew S. Lyon (0000-0002-2500-1013), ^{1,2}* Louise A. C. Millard, ² George Davey Smith, ^{1,2}
- 6 Tom R. Gaunt, 1,2 + Kate Tilling 1,2 +
- 8 1. National Institute for Health Research Bristol Biomedical Research Centre, University of
- 9 Bristol, Oakfield House, Bristol, BS8 2BN, UK
- 10 2. Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), Bristol Medical
- School (Population Health Sciences), University of Bristol, Oakfield House, Bristol, BS8
- 12 2BN, UK
- † These authors contributed equally to this work
- * To whom correspondence should be addressed. Tel: +44 (0) 117 331 4094; Email:
- 16 <u>matt.lyon@bristol.ac.uk;</u> Twitter: @matt_s_lyon

Abstract

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Blood biomarkers include disease intervention targets that may interact with genetic and environmental factors resulting in subgroups of individuals who respond differently to treatment. Such interactions may be observed in genetic effects on trait variance. Variance prioritisation is an approach to identify genetic loci with interaction effects by estimating their association with trait variance, even where the modifier is unknown or unmeasured. Here, we develop and evaluate a regression-based Brown-Forsythe test and variance effect estimate to detect such interactions. We provide scalable open-source software (varGWAS) for genome-wide association analysis of SNP-variance effects (https://github.com/MRCIEU/varGWAS) and apply our software to 30 blood biomarkers in UK Biobank. We find 468 variance quantitative trait loci across 24 biomarkers and follow up findings to detect 82 gene-environment and six gene-gene interactions independent of strong scale or phantom effects. Our results replicate existing findings and identify novel epistatic effects of TREH rs12225548 x FUT2 rs281379 and TREH rs12225548 x ABO rs635634 on alkaline phosphatase and ZNF827 rs4835265 x NEDD4L rs4503880 on gamma glutamyltransferase. These data could be used to discover possible subgroup effects for a given biomarker during preclinical drug development.

Introduction

Blood biomarkers provide valuable information for diagnosis and prognosis of disease¹, insight into biological mechanisms², and a source of causal modifiable risk factors which may be intervened upon to create therapies¹. For example, lipids, glucose, and urate have

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

become successful therapeutic targets for cardiovascular disease³, type 2 diabetes⁴, and gout⁵, respectively, among others. However, as biomarkers are complex traits they are affected by genetic and environmental factors which may interact producing gene-gene (GxG, epistasis) or gene-environment (GxE) effects⁶. Intervening on biomarkers which have an interaction effect on disease outcome will produce subgroup effects with individual variation in response to treatment dependent on the modifier⁷. Identifying these interactions may contribute to stratified medicine which aims to provide optimum treatments and preventative advice for disease based on individual characteristics⁶. Detecting interaction effects can be challenging. Statistical power to detect an interaction is lower than for main effects; for randomised control trials the sample size needed to detect an interaction with equal sized subgroups is around four times the size needed to detect the main effect of the same magnitude^{7,8}. Low power is exacerbated by multiple testing correction that is essential to account for evaluating the large numbers of candidate modifiers. To reduce multiple testing, pairwise interaction analyses of SNPs with moderate main effects can be performed. However, this approach could miss subgroups with an effect in only one group or opposing effect directionality (known as qualitative interaction effects) hence weaker overall effects, yet these offer the most potential for stratified medicine. An alternative approach to select SNPs for GxG/GxE testing is variance prioritisation ^{9,10} which identifies differences in outcome variance across genotype levels (variance quantitative trait loci, vQTL). Although not conclusive evidence, this observation is consistent with a SNPinteraction effect¹¹ and detection of vQTLs does not require the modifier to be measured¹¹.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Variance QTLs can arise as a consequence of heterogeneous mean effects that could occur from changing environment, background genetics and temporal regulation 11. Among the first reported vQTL effects in humans was rs7202116 (FTO locus), associated with a large change in variance (as well as mean) of body mass index (BMI)¹². More recently, systematic testing of vQTL effects on 13 quantitative traits in UK Biobank and subsequent GxE testing identified 16 GxE effects modified by age, sex, physical activity, sedentary behaviour, and smoking¹³. Variance QTLs have also been identified for gene expression¹⁴, DNA methylation¹⁵, Vitamin D¹⁶ and facial morphology¹⁷. To date, gene-interaction studies have mostly focused on testing a small number of candidate interactions, but hypothesis-free testing of vQTL effects on blood biomarkers could lead to the identification of unanticipated intervention targets with subgroup effects. Existing studies of vQTLs have employed a range of methods 13, 18-20. Wang et al compared the power and type I error of four widely used variance tests and found the median variant of Levene's test²¹ also known as the Brown-Forsythe test^{13,22} to be most robust. However, this test does not allow for inclusion of covariates or continuous genotype data (i.e., imputed allelic dose) and does not provide an effect estimate, all of which are limitations when applied in a GWAS. However, the Brown-Forsythe test can be reformulated using least-absolute deviation ^{15,23} (LAD) regression using the same structure as the Glejser test²⁴. Regression-based variance tests offer greater flexibility to overcome these limitations. Recent developments in LAD regression have vastly reduced the computational burden for large high-dimensional datasets²⁵.

In this study we compare the utility of the original Brown-Forsythe test and our LAD regression-based reformulation of the Brown-Forsythe test (LAD-BF) to detect SNP-interaction effects under simulation and develop scalable open-source software (https://github.com/MRCIEU/varGWAS) for performing variance GWAS using the latter. We apply our regression-based model to estimate SNP effects on the variance of 30 blood biomarkers in ~337K UK Biobank participants and follow up vQTLs with formal interaction tests to detect GxG and GxE interactions.

Material and methods

Original Brown-Forsythe test

- The Brown-Forsythe²² test (median variant of Levene's test²¹) refers to the original published non-parametric test and will be used throughout. We applied the Brown-Forsythe test to detect differences in trait variability across the three genotypic groups.
- The test statistic W is F-distributed F(2, N-3) given by:

$$W = \frac{(N-3)}{2} * \frac{\sum_{i=0}^{2} N_i (\bar{X}_i - \bar{X})^2}{\sum_{i=0}^{2} \sum_{j=1}^{N_i} (X_{ij} - \bar{X}_i)^2}$$

Where N is the total number of observations. N_i is the number of observations with the ith genotype group $\{0, 1, 2\}$. X_{ij} is the absolute residual of the outcome for the jth observation

in the ith genotype group from the median. \bar{X}_i is the mean of X_{ij} for the ith genotype group and \bar{X} is the mean of X_{ij} across genotype groups.

All analyses of the original Brown-Forsythe test used the omic-data-based complex trait analysis (OSCA) software package ^{13,26} which additionally produces a variance effect estimate derived from the test P-value assuming linearity between the SNP and outcome variance ²⁷.

LAD-BF test

Our reformulated regression-based Brown-Forsythe test uses LAD regression of outcome Y on independent variable X to estimate the residuals adjusting for any covariates:

$$Y = \widehat{\beta_0} + \widehat{\beta_1}X + \widehat{U}$$

Where X is the genotype measured by continuous (expected value from genotype imputation) or ordinal (directly genotyped) variable and \widehat{U} is the residual of this first-stage model.

A second-stage ordinary least squares (OLS) model regressed the absolute residuals $|\widehat{U}|$ of the first-stage model on the genotype values coded as dummy variables (genotype expected values were rounded to the nearest whole number resulting in some loss of precision) including any covariates given in the first-stage model:

$$|U| = \widehat{\gamma}_0 + \widehat{\gamma}_1 X 1 + \widehat{\gamma}_2 X 2 + \widehat{E}$$

131 The test P-value was estimated from an F-test comparing the second-stage residual sum of

squares to an intercept-only model to test the null hypothesis of variability homogeneity

across genotypes.

SNP effects on trait variance were calculated from second-stage regression coefficients

which are estimates of mean-absolute deviation. This transformation assumes trait

137 normality.

130

132

133

134

135

136

142

143

144

145

146

147

148

149

150

138 The var(Y|G == 1) was estimated using:

$$2 * \widehat{\gamma_0} + \widehat{\gamma_1} + \widehat{\gamma_1^2} / (\frac{2}{pi})$$

The var(Y|G == 2) was estimated using:

$$2 * \widehat{\gamma}_0 + \widehat{\gamma}_2 + \widehat{\gamma}_2^2 / (\frac{2}{pi})$$

140 The standard error of the variance effect was estimated using the delta method²⁸ and

141 heteroscedastic-consistent standard errors for the second-stage model coefficients²⁹.

LAD regression was implemented using the majorise-minimisation 25,30 (MM) model with

default values for iterations (200) and tolerance (0.001) and first-stage OLS regression

coefficients provided as initial values.

Software

The LAD-BF test was implemented in varGWAS available in C++ v1.2.3 and R v1.0.0 (refer to

the code and data availability section). The MM model used functionality from the cqrReg R-

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

package²⁵ (https://cran.r-project.org/web/packages/cgrReg/index.html). OLS and general matrix functionality were provided with Eigen v3.4.0³¹. BGEN file processing used the BGEN library³² v1.1.6. The original Brown-Forsythe test used the OSCA software package v0.46^{13,26}. Simulations and follow up UK Biobank analyses were performed using R v3.6.0. **Simulations** The bias and statistical power of the two Brown-Forsythe tests were evaluated through a series of simulation studies reported using the ADEMP structure³³ (Table 1 & Supplemental Material and Methods). **Participants** UK Biobank is a large prospective cohort study of approximately 500,000 UK participants aged 37-73 at recruitment³⁴. Recruitment took place between 2006-2010 from across the UK. Measures were collected on lifestyle, socio-demographics, physical parameters, healthrelated factors, and biological samples for genetic testing and biomarker measurements. Ethical approval for the UK Biobank study was granted by the National Research Ethics Service (NRES) Committee North West (ref 11/NW/0382). All analyses were performed under approved UK Biobank project 15825 (dataset ID 33352).

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Genetic data Genetic array data were available on 488,377 participants measured using a combination of UK Biobank Axiom[™] array (n=438.398) and UK BiLEVE array (n=49.979). Genotype imputation was performed using a reference set combined with UK10K haplotypes and HRC reference panels with the IMPUTE2³⁵ software as described³⁶. The following SNPs were removed from analysis leaving a total of 6,812,700: multi-allelic loci, minor allele frequency < 5%, Hardy-Weinberg violations (P $< 1 \times 10^{-5}$), genotype missing rate > 5%, low imputation score (INFO < 0.3) and HLA locus (hg19/GRCh37 chr6:23477797-38448354). Quality control We applied standard exclusion criteria (Figure S1) to remove genotype-phenotype sex mismatches, aneuploidies, and outliers for missingness or heterozygosity as previously described 36 leaving n=486,565 participants. To ensure data independence, closely related subjects were removed as described elsewhere ³⁶ leaving n=407,176 participants. Finally, 'non-white British' participants defined using published methodology³⁶ were removed to avoid confounding by population stratification providing a total sample size of n=377,076. Phenotypes UK Biobank measures of 30 serum biochemistry markers were available for approximately 500k participants. Each measure was chosen based on being an established risk factor for disease, a clinical diagnostic measure or because it characterises a phenotype that is not

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

well assessed by other approaches as described in the UK Biobank documentation³⁷. Quantification and quality control was performed as previously described³⁷. Total physical activity was calculated by summing self-reported duration of walking, moderate and vigorous activity collected using the International Physical Activity Questionnaire as described³⁸. For each analysis participants with missing data were removed. All continuous outcomes were SD normalised. Genome-wide association studies (GWAS) GWAS of biomarker variability were performed using our LAD regression-based Brown-Forsythe test adjusted for age, sex, and the top ten genetic principal components in first and second regression models. We removed outlier biomarker values with a Z-score > 5SD from the mean to control type I error inflation as previously described 13. Quality control was undertaken visually using Q-Q plots to check for a departure of P-value distribution from that expected under the null. Independent vQTLs were identified by clumping GWAS loci that passed the experiment-wise genome-wide evidence threshold P < 1.67 \times 10⁻⁹ (Bonferroni correction of standard GWAS threshold: $p = 5 \times 10^{-8} / 30$) using the OpenGWAS API³⁹ with default R² threshold of 0.001 and 1000 genomes phase 3 European ancestry⁴⁰. Gene interaction test Independent vQTLs (see above) were tested for interaction effects on additive and multiplicative scales using heteroscedasticity-consistent standard errors²⁹ adjusted for age, sex, and top ten genetic principal components. To ensure effects were robust to phantom

effects⁴¹, we performed sensitivity analyses adjusting for fine-mapped main effects identified using SuSiE⁴² (**Supplemental Material and Methods**). Interactions surpassing genome-wide association significance ($P < 5 \times 10^{-8}$) on additive and multiplicative scales that did not strongly attenuate with adjustment for fine-mapped main effects were prioritised for subgroup analyses. GxG effects were identified through interaction testing with independent ($R^2 < 0.001$) vQTLs excluding pairwise combinations of vQTLs within a 10Mb window as previously described¹³. GxE testing was performed using candidate modifiers: age, sex, body mass index, alcohol intake, smoking status, physical activity, daily sugar intake, and daily fat intake.

Subgroup analyses

Subgroup effects of top interaction effects were presented by estimating the SNP effect on the outcome stratified by modifier using heteroscedasticity-consistent standard errors²⁹ adjusted for age, sex and top ten genetic principal components. Modifiers were rounded genetic dosage values or prepared by dichotomisation as follows: below or above the median value for continuous variables (group [G] 1, below median; G2, median or greater), ever (G1) vs never (G2) smoker, alcohol intake once a week or more (G1) vs less than once a week on average (G2), males (G1) vs females (G2). Subgroup effects are presented along with the SNP-variance estimates adjusted for age, sex and top ten genetic principial components with and without adjustment for the interaction term (variance effects were not adjusted for sex when sex was the modifier).

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

Gene annotation Variance QTLs were annotated with the nearest gene using the closest function of bedtools⁴³ (v2.3.0) and Ensembl v104 (GRCh37) protein-coding features which were filtered to retain HUGO⁴⁴ valid identifiers. The following annotations were recoded based on expression QTL evidence^{45,46}: rs4530622 *SLC2A9*, rs11244061 *ABO*, rs71633359 *HSD17B13*, rs28413939 TREH, rs281379 FUT2, rs635634 ABO, rs964184 APOA5. Results Simulated power and type I error to detect interaction effects by change in variance The power to detect a difference in trait variability due to an interaction effect was low and equivalent for both methods (Figure S2). Suppose a SNP has a main effect on a normally distributed outcome detectable with 80% power, then 10x the sample size needed to detect the main effect was required to detect the interaction with only 50% power assuming the interaction was half the size of the main effect. Positive skew and kurtosis reduced power. Both methods had equally well controlled type I error (Figure S3). Simulated variance effect estimate and confidence interval coverage Under a simulated linear effect of genotype on outcome variance both methods gave the correct effect estimate and 95% confidence interval coverage (Figure 1). However, when the difference in variance was a consequence of an interaction effect, the relationship between

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

the genotype and outcome variance was non-linear and dependent on the modifier. Under these conditions, the variance effect estimate produced using OSCA^{26,27} from the Brown-Forsythe test P-value gave the incorrect effect size while LAD-BF produced the correct estimate albeit with slightly elevated coverage. Adjusting the LAD-BF test for an interaction effect through simulation We simulated an interaction effect and compared the LAD-BF test P-value distributions with and without adjusting for the simulated interaction (Figure S4). Including the interaction term in the first-stage regression model completely attenuated the variance test statistic. After identifying an interaction at a variance locus this approach could be applied to determine if additional strong interaction effects exist and could be used in a stepwise regression fashion until all interaction effects are identified. Runtime performance Increasing the number of CPU threads reduced the total runtime of both methods to process 1000 SNPs (Figure S5). For the C++ implementation of LAD-BF in varGWAS, the lowest average runtime was 13.6 second (95% CI 13.5, 13.7) using four threads of an Intel(R) Xeon(R) CPU E5-2680 v4 @ 2.40GHz. Under the same conditions, the original Brown-Forsythe test implemented in OSCA was 1.78x faster (7.61 seconds [95% CI 7.60, 7.63]). GWAS of variance effects in UK Biobank

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

We identified 468 independent (R² < 0.001) vQTLs influencing 24 biomarkers (Figure S6, Figure S7 & Table S1) using an experiment-wise P-value threshold of 1.67 x 10⁻⁹ (5 x 10⁻⁸ / 30) and no variance effects for albumin, calcium, oestradiol, phosphate, rheumatoid factor, or total protein. Oestradiol and rheumatoid factor were measured on a subset of n=76,674 and n=41,315 participants respectively and therefore were less well powered to detect effects. Of these vQTLs, 270 (57.7%) had suggestive evidence for a variance effect on the log scale (P < 5 x 10^{-5}) and 453 (96.8%) had a mean effect (P < 5 x 10^{-8}). The low concordance between natural and log scales and high concordance between mean and variance effects suggests the presence of mean-variance relationships which is a likely consequence of extreme non-normality for some of the trait distributions (Figure S8). Gene-environment interaction effects (GxE) We detected 139 additive and 104 multiplicative GxE effects (P < 5 x 10⁻⁸; Figure S9 & Figure \$10). Adjusting the additive effects for fine-mapped main effects (Figure \$11) led to a small increase in UGT1A8 rs2741047 x sex on direct bilirubin to 0.037 SD (95% CI 0.032, 0.042) from 0.028 SD (95% CI 0.023, 0.033) and minor attenuation of MAP3K4 rs1247295 x sex on lipoprotein a to -0.011 SD (95% CI -0.015, -0.007) from -0.016 SD (95% CI -0.021, -0.010). These findings could reflect the presence of large main effects in imperfect linkage disequilibrium with the index SNP which is known to inflate/deflate test statistics⁴¹. We prioritised 82 GxE effects with evidence on both scales ($P < 5 \times 10^{-8}$) to avoid spurious interactions dependent on scale (Table S2). Of these BMI (n=35), sex (n=27) and age (n=17) modified most effects and smoking status (n=2) and alcohol intake (n=1) fewer. We also

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

tested for interaction by physical activity, and sugar and fat intake but identified little evidence of interactions. The largest effects (Figure 2) were: PNPLA3 rs738409 x BMI on alanine aminotransferase (ALT; 0.08 SD [95% CI 0.08, 0.09]), SLC2A9 rs938555 x sex on urate (-0.08 SD [95% CI -0.09, -0.08]), APOE rs1065853 x sex on low-density lipoprotein (LDL; 0.06) SD [95% CI 0.05, 0.07]), SHBG rs1799941 x sex on testosterone (0.06 SD [95% CI 0.06, 0.06]) and TM6SF2 rs58542926 x BMI on ALT (0.05 SD [95% CI 0.04, 0.06]). Adjusting the variance effect for the interaction term (Figure 2) led to attenuation of PNPLA3 rs738409 and TM6SF2 rs58542926 on ALT and SHBG rs1799941 on testosterone but strong variance effects on ALT remained at PNPLA3 rs738409 (LAD-BF P adjust = 1.0 x 10⁻⁷³) and TM6SF2 rs58542926 (LAD-BF P adjust = 1.84 x 10⁻⁸). There was no strong variance attenuation of APOE rs1065853 on LDL or SLC2A9 rs938555 on urate following adjustment for the interaction (Figure 2). Gene-gene interaction effects (GxG) We detected eight GxG effects on the additive scale ($P < 5 \times 10^{-8}$; Figure S12), six of which were also associated on the multiplicative scale ($P < 5 \times 10^{-8}$; Figure S13). There was no strong attenuation following adjustment for fine-mapped main effects (Figure S14) suggesting phantom epistasis 41,47 was not a major source of bias. ZNF827 rs4835265 x NEDD4L rs4503880 was inversely associated with -0.04 SD (95% CI -0.05, -0.03) gamma glutamyltransferase (GGT), ABO rs635634 x FUT2 rs281379, ABO rs635634 x TREH rs12225548, and TREH rs12225548 x FUT2 rs281379 were associated with 0.08 SD (95% CI 0.07, 0.09), 0.04 SD (95% CI 0.03, 0.05) and 0.02 SD (95% CI 0.02, 0.03) increase in alkaline phosphatase (ALP) respectively, HSD17B13 rs71633359 x PNPLA3 rs738409 and HSD17B13

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

rs71633359 x PNPLA3 rs3747207 were associated with -0.04 SD (95% CI -0.05, -0.03) and -0.04 SD (95% CI -0.05, -0.03) decrease in ALT and aspartate aminotransferase (AST) respectively (Figure 3). Adjusting the variance effects for the interaction term had no strong impact on the variance estimate (Figure 3). Discussion Here we demonstrate the value of variance GWAS in identifying 468 independent vQTLs with evidence of interaction on 24 serum biochemistry phenotypes in UK Biobank and subsequently identify 82 GxE and six GxG scale independent effects. To facilitate this largescale analysis on ~337K UK Biobank participants we developed an efficient C++ implementation of a LAD regression-based Brown-Forsythe test²² (implemented in varGWAS) with functionality to reliably estimate variance effects and compared the test with the original non-parametric version (implemented in OSCA 13,26) through a series of simulations. Although the power to detect genetic interaction effects using variance prioritisation was low, when applied to large sample sizes such as UK Biobank strong evidence for association can be identified as demonstrated in this study and by Wang et al¹³. We found LAD-BF had several advantages over the original non-parametric test when applied to GWAS. First, LAD-BF directly supports adjustment for covariates (although this could be achieved using the original test if applied to pre-adjusted phenotypes¹³). Second, LAD-BF can test effects of continuous genotypes which enables application to the expected genotype value ("dose") from imputed SNP array data. Third, our model provides a variance effect estimate which is

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

valid when there is a SNP interaction effect, unlike the implementation of the original Brown-Forsythe test in OSCA which provides an incorrect variance effect estimate derived from the test P-value²⁷. We also demonstrate through simulation that adjusting the variance effect for the interaction term causes attenuation which is useful to determine if other interactions exist and could potentially be applied using stepwise regression until all interaction effects are discovered, subject to sufficient power. However, there are some disadvantages. The runtime was 75% longer than the original test implemented in OSCA, although this is still fast enough to allow large-scale analyses. Second, the effect estimate (but not test statistic) is based on normality assumptions which may be violated in practice. The largest GxE effects replicate existing findings: PNPLA3 rs738409 x BMI on ALT levels 48,49. SLC2A9 rs938555 x sex on urate⁵⁰, APOE rs1065853 x sex on LDL⁵¹, SHBG rs1799941 x sex on testosterone⁵², and *TM6SF2* rs58542926 x BMI on ALT⁴⁸. Adjusting the variance effect for the interaction led to attenuation of PNPLA3 rs738409 and TM6SF2 rs58542926 on ALT and SHBG rs1799941 on testosterone, however strong evidence of variance effects remained for ALT at PNPLA3 rs738409 and TM6SF2 rs58542926 suggesting other interaction effects may exist at these loci. The variance effect of SHBG rs1799941 on testosterone was weak after adjusting for rs1799941 x sex suggesting no strong evidence of further interaction effects on testosterone at this locus, but the test may be underpowered to detect additional effects. We replicated previous GxG effects of ABO rs635634 x FUT2 rs281379 on ALP^{53,54} and HSD17B13 rs71633359 x PNPLA3 rs738409/rs3747207 on ALT and AST^{55,56} and find no strong evidence of 'phantom epistasis' 41,47 as a potential explanation. Additionally, we identified novel effects of TREH rs12225548 x FUT2 rs281379 and ABO rs635634 x TREH

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

rs12225548 on ALP and ZNF827 rs4835265 x NEDD4L rs4503880 on GGT. ABO blood group antigens and secretion status are thought to influence ALP clearance 57,58. TREH rs12225548 has a strong main effect on ALP^{39,59,60} and interactions of these loci may be explained by interplay of ALP production and clearance mechanisms. ZNF827 and NEDD4L loci have previously been reported to influence GGT levels in independent populations but the mechanism is unclear 61,62. None of the GxG loci variance effects strongly attenuated after adjusting for the interaction term. This could be a consequence of low power since the interaction effect likely explains a very small amount of the trait variance but could also indicate the presence of other interaction effects involving the same SNP not included in the variance model. Indeed, we found strong GxE evidence at some of these loci: ABO rs635634 x sex on ALP, HSD17B13 rs71633359 x BMI and PNPLA3 rs738409/rs3747207 x BMI on ALT and AST. Evidence of gene-interaction effects could suggest the protein product also has an interaction effect. In which case interventions developed to target the protein will show differential effects on the indication and could have low or no efficacy in some subgroups 63. Such evidence could be important to support developments in stratified medicine. Therefore, vQTL evidence may have a role in preclinical drug development to deprioritise targets given the possibility of target-outcome heterogeneous effects. Further research is needed to appraise the utility of vQTLs in the drug development pipeline as has been done for protein QTLs⁶⁴.

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

However, there are other explanations for vQTLs that are not in terms of biology. First, loci that are weakly correlated with a SNP having a strong main effect can introduce a phantom vQTL^{65,66}. In this situation variance is introduced through variability in LD between the artefactual vQTL and QTL. Second, vQTLs could signify fluctuation of a trait measurement within an individual over time ¹⁰ and may originate from normal biological processes such as circadian rhythm. Third, we assume homogeneity of variance within each genotype group which could be violated by the mean-variance relationship and observed low concordance of vQTL effects on the log and natural scales are evidence for this. Additionally, our interactions could be explained by non-linear relationships between the exposure and outcome or scale artefacts⁶⁷. We sought to reduce the latter by replicating effects on additive and multiplicative scales. Through this work we performed hypothesis-free analyses of genetic interaction effects on 30 blood biomarkers in UK Biobank using variance prioritisation and found evidence for 88 effects. Many of our top findings replicate previously reported associations, but we also report first evidence of TREH rs12225548 x FUT2 rs281379 and TREH rs12225548 x ABO rs635634 on ALP and ZNF827 rs4835265 x NEDD4L rs4503880 on GGT. Additionally, we show variance attenuation of PNPLA3 rs738409 and TM6SF2 rs58542926 on ALT and SHBG rs1799941 on testosterone after adjusting for the interaction indicating these effects were contributing to the variance association, but the ALT effects were still strong suggesting additional interactions may exist at these loci. These data could be used to discover possible subgroup effects for a given biomarker during preclinical drug development. To facilitate our analysis, we developed C++ variance GWAS software that implements a LAD-regression based Brown-Forsythe test, provide a convenient R-package based on this software and

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

introduce methodology to estimate the variance effects which can be applied to other studies. Supplemental information description Supplemental Material and Methods Figure S1. UK Biobank participant inclusion criteria Figure S2. Power to detect SNP-interaction effects using variance testing under simulation Figure S3. Type I error of Brown-Forsythe tests Figure S4. Effect of adjustment for the interaction effect on variance test P-value distribution Figure S5. Runtime performance of varGWAS and OSCA Figure S6. Manhattan plots of biomarker variance GWAS using regression-based Brown-Forsythe test Figure S7. Q-Q plots of biomarker variance GWAS using regression-based Brown-Forsythe test Figure S8. Biomarker distribution Figure S9. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using additive scale Figure S10. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using multiplicative scale Figure S11. Top gene-by-environment interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using additive scale adjusted for fine-mapped main effect

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

Figure S12. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using additive scale Figure S13. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using multiplicative scale Figure S14. Top gene-by-gene interaction effects ($P < 5 \times 10^{-8}$) on biomarker concentration using additive scale adjusted for fine-mapped main effects Table S1. GWAS summary statistics for top vQTLs identified through this study Table S2. Top GxG/GxE effect summary statistics Table S3. Fine-mapped loci covariates **Declaration of Interests** T.R.G receives funding from Biogen for unrelated research. K.T has been paid for consultancy for CHDI. Acknowledgements This study was funded by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was also funded by the UK Medical Research Council as part of the MRC Integrative Epidemiology Unit (MC UU 00011/1, MC UU 00011/3 and MC UU 00011/4). L.A.C.M is funded by a University of Bristol Vice-Chancellor's fellowship.

Code and data availability

Software to perform variance GWAS using the LAD Brown-Forsythe model is available from https://github.com/MRCIEU/varGWAS and R-package for *ad hoc* analyses is available from https://github.com/MRCIEU/varGWASR. Code for performing simulation studies is available from https://github.com/MRCIEU/varGWAS/sim. Code for running the UK Biobank analysis is available from https://github.com/MRCIEU/varGWAS-ukbb-biomarkers. Full variance GWAS summary statistics are available from the OpenGWAS project^{39,68}. All code repositories are available under the GPL v3 license.

References

492

- 494 1. Holmes, M. V., Richardson, T.G., Ference, B.A., Davies, N.M., and Davey Smith, G. (2021).
- 495 Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular
- 496 drug development. Nat. Rev. Cardiol. 18, 435-453.
- 497 2. Chen, V.L., Du, X., Chen, Y., Kuppa, A., Handelman, S.K., Vohnoutka, R.B., Peyser, P.A.,
- 498 Palmer, N.D., Bielak, L.F., Halligan, B., et al. (2021). Genome-wide association study of serum
- 499 liver enzymes implicates diverse metabolic and liver pathology. Nat. Commun. 2021 121 12,
- 500 1**-**13.
- 3. Pekkanen, J., Linn, S., Heiss, G., Suchindran, C.M., Leon, A., Rifkind, B.M., and Tyroler, H.A.
- 502 (2010). Ten-Year Mortality from Cardiovascular Disease in Relation to Cholesterol Level
- among Men with and without Preexisting Cardiovascular Disease. NEJM 322, 1700–1707.
- 4. Diabetes Prevention Program Research Group (2002). Reduction of the incidence of type
- 505 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 34, 162–163.
- 506 5. Seth, R., Kydd, A.S., Buchbinder, R., Bombardier, C., and Edwards, C.J. (2014). Allopurinol
- for chronic gout. Cochrane Database Syst. Rev. 2014.
- 6. Hunter, D.J. (2005). Gene-environment interactions in human diseases. Nat. Rev. Genet.
- 509 2005 64 *6*, 287–298.
- 7. Brookes, S.T., Whitely, E., Egger, M., Davey Smith, G., Mulheran, P.A., and Peters, T.J.
- 511 (2004). Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power
- and sample size for the interaction test. J. Clin. Epidemiol. *57*, 229–236.
- 8. Smith, P.G., and Day, N.E. (1984). The Design of Case-Control Studies: The Influence of
- 514 Confounding and Interaction Effects. Int. J. Epidemiol. 13, 356–365.
- 9. Deng, W.Q., and Paré, G. (2011). A fast algorithm to optimize SNP prioritization for gene-

- gene and gene-environment interactions. Genet. Epidemiol. 35, 729–738.
- 517 10. Paré, G., Cook, N.R., Ridker, P.M., and Chasman, D.I. (2010). On the Use of Variance per
- 518 Genotype as a Tool to Identify Quantitative Trait Interaction Effects: A Report from the
- Women's Genome Health Study. PLoS Genet. 6, e1000981.
- 520 11. Rönnegård, L., and Valdar, W. (2012). Recent developments in statistical methods for
- 521 detecting genetic loci affecting phenotypic variability. BMC Genet. 2012 131 13, 1–7.
- 12. Yang, J., Loos, R.J.F., Powell, J.E., Medland, S.E., Speliotes, E.K., Chasman, D.I., Rose, L.M.,
- 523 Thorleifsson, G., Steinthorsdottir, V., Mägi, R., et al. (2012). FTO genotype is associated with
- 524 phenotypic variability of body mass index. Nature 490, 267–272.
- 13. Wang, H., Zhang, F., Zeng, J., Wu, Y., Kemper, K.E., Xue, A., Zhang, M., Powell, J.E.,
- 526 Goddard, M.E., Wray, N.R., et al. (2019). Genotype-by-environment interactions inferred
- from genetic effects on phenotypic variability in the UK Biobank. Sci. Adv. 5, eaaw3538.
- 528 14. Brown, A.A., Buil, A., Viñuela, A., Lappalainen, T., Zheng, H.F., Richards, J.B., Small, K.S.,
- 529 Spector, T.D., Dermitzakis, E.T., and Durbin, R. (2014). Genetic interactions affecting human
- 530 gene expression identified by variance association mapping. Elife 2014, e01381.
- 15. Staley, J.R., Windmeijer, F., Suderman, M., Lyon, M.S., Davey Smith, G., and Tilling, K.
- 532 (2021). A robust mean and variance test with application to high-dimensional phenotypes.
- 533 Eur. J. Epidemiol. 1, 1–11.
- 16. Revez, J.A., Lin, T., Qiao, Z., Xue, A., Holtz, Y., Zhu, Z., Zeng, J., Wang, H., Sidorenko, J.,
- Kemper, K.E., et al. (2020). Genome-wide association study identifies 143 loci associated
- with 25 hydroxyvitamin D concentration. Nat. Commun. 2020 111 11, 1–12.
- 537 17. Liu, D., Ban, H.-J., El Sergani, A.M., Lee, M.K., Hecht, J.T., Wehby, G.L., Moreno, L.M.,
- 538 Feingold, E., Marazita, M.L., Cha, S., et al. (2021). PRICKLE1 × FOCAD Interaction Revealed by
- 539 Genome-Wide vQTL Analysis of Human Facial Traits. Front. Genet. 0, 1112.

- 18. Young, A.I., Wauthier, F.L., and Donnelly, P. (2018). Identifying loci affecting trait
- variability and detecting interactions in genome-wide association studies. Nat. Genet. 50,
- 542 1608**-**1614.
- 19. Dumitrascu, B., Darnell, G., Ayroles, J., and Engelhardt, B.E. (2019). Statistical tests for
- detecting variance effects in quantitative trait studies. Bioinformatics 35, 200–210.
- 545 20. Corty, R.W., and Valdar, W. (2018). QTL mapping on a background of variance
- heterogeneity. G3 Genes, Genomes, Genet. 8, 3767–3782.
- 21. Levene, H. (1960). Robust testes for equality of variances. Contrib. to Probab. Stat. 278–
- 548 292.
- 549 22. Brown, M.B., and Forsythe, A.B. (1974). Robust tests for the equality of variances. J. Am.
- 550 Stat. Assoc. *69*, 364–367.
- 23. Soave, D., and Sun, L. (2017). A generalized Levene's scale test for variance
- heterogeneity in the presence of sample correlation and group uncertainty. Biometrics 73,
- 553 960**-**971.
- 554 24. Glejser, H. (1969). A New Test for Heteroskedasticity. J. Am. Stat. Assoc. 64, 316.
- 555 25. Pietrosanu, M., Gao, J., Kong, L., Jiang, B., and Niu, D. (2020). Advanced algorithms for
- penalized quantile and composite quantile regression. Comput. Stat. 2020 361 36, 333–346.
- 557 26. Zhang, F., Chen, W., Zhu, Z., Zhang, Q., Nabais, M.F., Qi, T., Deary, I.J., Wray, N.R.,
- Visscher, P.M., McRae, A.F., et al. (2019). OSCA: a tool for omic-data-based complex trait
- 559 analysis. Genome Biol. 2019 201 20, 1–13.
- 27. Zhu, Z., Zhang, F., Hu, H., Bakshi, A., Robinson, M.R., Powell, J.E., Montgomery, G.W.,
- 561 Goddard, M.E., Wray, N.R., Visscher, P.M., et al. (2016). Integration of summary data from
- 562 GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481–487.
- 563 28. Oehlert, G.W. (1992). A Note on the Delta Method. Source Am. Stat. 46, 27–29.

- 564 29. White, H. (1980). A Heteroskedasticity-Consistent Covariance Matrix Estimator and a
- 565 Direct Test for Heteroskedasticity. Econometrica 48, 817.
- 30. Hunter, D.R., and Lange, K. (2000). Quantile Regression via an MM Algorithm. J. Comput.
- 567 Graph. Stat. 9, 60.
- 31. Guennebaud, G., Jacob, B., and others (2010). Eigen v3.
- 32. Band, G., and Marchini, J. (2018). BGEN: a binary file format for imputed genotype and
- 570 haplotype data. BioRxiv 308296.
- 33. Morris, T.P., White, I.R., and Crowther, M.J. (2019). Using simulation studies to evaluate
- statistical methods. Stat. Med. 38, 2074–2102.
- 34. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
- 574 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep
- 575 phenotyping and genomic data. Nature *562*, 203–209.
- 576 35. Howie, B., Marchini, J., and Stephens, M. (2011). Genotype imputation with thousands
- of genomes. G3 Genes, Genomes, Genet. 1, 457–470.
- 578 36. Mitchell, R.E., Hemani, G., Dudding, T., Corbin, L., Harrison, S., and Paternoster, L. UK
- 579 Biobank Genetic Data: MRC-IEU Quality Control, version 2, 18/01/2019.
- 580 37. Fry, D., Almond, R., Moffat, S., Gordon, M., and Singh, P. (2019). UK Biobank Biomarker
- Project Companion Document to Accompany Serum Biomarker Data.
- 38. Cassidy, S., Chau, J.Y., Catt, M., Bauman, A., and Trenell, M.I. (2016). Cross-sectional
- 583 study of diet, physical activity, television viewing and sleep duration in 233 110 adults from
- the UK Biobank; the behavioural phenotype of cardiovascular disease and type 2 diabetes.
- 585 BMJ Open 6, e010038.
- 586 39. Elsworth, B., Lyon, M., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer,
- 587 T., Haberland, V., Davey Smith, G., et al. (2020). The MRC IEU OpenGWAS data

- 588 infrastructure. BioRxiv 2020.08.10.244293.
- 40. Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A.,
- Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., et al. (2015). A global reference for human
- 591 genetic variation. Nat. 2015 5267571 526, 68–74.
- 41. Hemani, G., Powell, J.E., Wang, H., Shakhbazov, K., Westra, H.-J., Esko, T., Henders, A.K.,
- 593 McRae, A.F., Martin, N.G., Metspalu, A., et al. (2021). Phantom epistasis between unlinked
- 594 loci. Nat. 2021 5967871 *596*, E1–E3.
- 42. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach to
- 596 variable selection in regression, with application to genetic fine mapping. J. R. Stat. Soc. Ser.
- 597 B (Statistical Methodology). *82*, 1273–1300.
- 43. Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing
- 599 genomic features. Bioinforma. Appl. NOTE 26, 841–842.
- 44. Tweedie, S., Braschi, B., Gray, K., Jones, T.E.M., Seal, R.L., Yates, B., and Bruford, E.A.
- 601 (2021). Genenames.org: The HGNC and VGNC resources in 2021. Nucleic Acids Res. 49,
- 602 D939-D946.
- 45. Võsa, U., Claringbould, A., Westra, H.-J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
- Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL analyses
- identify thousands of genetic loci and polygenic scores that regulate blood gene expression.
- 606 Nat. Genet. 2021 539 *53*, 1300–1310.
- 607 46. GTEx Portal, https://gtexportal.org.
- 47. Campos, G. de los, Sorensen, D.A., and Toro, M.A. (2019). Imperfect Linkage
- 609 Disequilibrium Generates Phantom Epistasis (& Perils of Big Data). G3 Genes, Genomes,
- 610 Genet. 9, 1429–1436.
- 611 48. Stender, S., Kozlitina, J., Nordestgaard, B.G., Tybjaerg-Hansen, A., Hobbs, H.H., and

- 612 Cohen, J.C. (2017). Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by
- Multiple Loci HHS Public Access Author manuscript. Nat Genet 49, 842–847.
- 49. Viitasalo, A., Pihlajamaki, J., Lindi, V., Atalay, M., Kaminska, D., Joro, R., and Lakka, T.A.
- 615 (2015). Associations of I148M variant in PNPLA3 gene with plasma ALT levels during 2-year
- 616 follow-up in normal weight and overweight children: The PANIC Study. Pediatr. Obes. 10,
- 617 84-90.
- 50. Döring, A., Gieger, C., Mehta, D., Gohlke, H., Prokisch, H., Coassin, S., Fischer, G., Henke,
- 619 K., Klopp, N., Kronenberg, F., et al. (2008). SLC2A9 influences uric acid concentrations with
- 620 pronounced sex-specific effects. Nat. Genet. 2008 404 40, 430–436.
- 51. Ferrières, J., Sing, C.F., Roy, M., Davignon, J., and Lussier-Cacan, S. (1994).
- Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia. Sex-
- 623 specific effects. Arterioscler. Thromb. a J. Vasc. Biol. 14, 1553–1560.
- 52. Ruth, K.S., Day, F.R., Tyrrell, J., Thompson, D.J., Wood, A.R., Mahajan, A., Beaumont,
- 625 R.N., Wittemans, L., Martin, S., Busch, A.S., et al. (2020). Using human genetics to
- 626 understand the disease impacts of testosterone in men and women. Nat. Med. 2020 262 26,
- 627 252-258.
- 53. Masuda, M., Okuda, K., Ikeda, D.D., Hishigaki, H., and Fujiwara, T. (2015). Interaction of
- 629 genetic markers associated with serum alkaline phosphatase levels in the Japanese
- 630 population. Hum. Genome Var. 2015 21 2, 1–6.
- 631 54. Langman, M.J.S., Leuthold, E., Robson, E.B., Harris, J., Luffman, J.E., and Harris, H. (1966).
- 632 Influence of diet on the "intestinal" component of serum alkaline phosphates in people of
- different ABO blood groups and secretor status. Nature *212*, 41–43.
- 634 55. Abul-Husn, N.S., Cheng, X., Li, A.H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J.,
- 635 Stender, S., Wood, G.C., et al. (2018). A Protein-Truncating HSD17B13 Variant and

- 636 Protection from Chronic Liver Disease. NEJM 378, 1096–1106.
- 637 56. Gellert-Kristensen, H., Richardson, T.G., Davey Smith, G., Nordestgaard, B.G., Tybjærg-
- Hansen, A., and Stender, S. (2020). Combined Effect of PNPLA3, TM6SF2, and HSD17B13
- 639 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
- 640 Hepatology 72, 845-856.
- 57. Bayer, P.M., Hotschek, H., and Knoth, E. (1980). Intestinal alkaline phosphatase and the
- ABO blood group system--a new aspect. Clin. Chim. Acta. 108, 81–87.
- 58. Nakano, T., Shimanuki, T., Matsushita, M., Koyama, I., Inoue, I., Katayama, S., Alpers,
- 644 D.H., and Komoda, T. (2006). Involvement of intestinal alkaline phosphatase in serum
- apolipoprotein B-48 level and its association with ABO and secretor blood group types.
- Biochem. Biophys. Res. Commun. 341, 33–38.
- 59. Neale, B., et al. UK Biobank GWAS, http://www.nealelab.is/uk-biobank
- 648 60. Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N.,
- 649 Ikegawa, S., Hirata, M., Matsuda, K., et al. (2018). Genetic analysis of quantitative traits in
- 650 the Japanese population links cell types to complex human diseases. Nat. Genet. 50, 390-
- 651 400.
- 652 61. Young, K.A., Palmer, N.D., Fingerlin, T.E., Langefeld, C.D., Norris, J.M., Wang, N., Xiang,
- 653 A.H., Guo, X., Williams, A.H., Chen, Y.D.I., et al. (2019). Genome-Wide Association Study
- 654 Identifies Loci for Liver Enzyme Concentrations in Mexican-Americans: The GUARDIAN
- 655 Consortium. Obesity (Silver Spring). 27, 1331.
- 656 62. Chambers, J.C., Zhang, W., Sehmi, J.S., Li, X., Wass, M.N., Van der Harst, P., Holm, H.,
- 657 Sanna, S., Kavousi, M., Baumeister, S.E., et al. (2011). Genome-wide association study
- 658 identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 2011 4311
- 659 *43*, 1131–1138.

- 660 63. Xu, Z.M., and Burgess, S. (2020). Polygenic modelling of treatment effect heterogeneity.
- 661 Genet. Epidemiol. 44, 868-879.
- 662 64. Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P.C., Hurle, M.R., Gutteridge, A.,
- 663 Erola, P., Liu, Y., Luo, S., et al. (2020). Phenome-wide Mendelian randomization mapping the
- influence of the plasma proteome on complex diseases. Nat. Genet. 2020 5210 52, 1122-
- 665 1131.
- 666 65. Cao, Y., Wei, P., Bailey, M., Kauwe, J.S.K., and Maxwell, T.J. (2014). A versatile omnibus
- test for detecting mean and variance heterogeneity. Genet. Epidemiol. 38, 51–59.
- 668 66. Ek, W.E., Rask-Andersen, M., Karlsson, T., Enroth, S., Gyllensten, U., and Johansson, Å.
- 669 (2018). Genetic variants influencing phenotypic variance heterogeneity. Hum. Mol. Genet.
- 670 *27*, 799–810.
- 67. Rees, J.M.B., Foley, C.N., and Burgess, S. (2020). Factorial Mendelian randomization:
- 672 using genetic variants to assess interactions. Int. J. Epidemiol. 49, 1147–1158.
- 673 68. Lyon, M.S., Andrews, S.J., Elsworth, B., Gaunt, T.R., Hemani, G., and Marcora, E. (2021).
- The variant call format provides efficient and robust storage of GWAS summary statistics.
- 675 Genome Biol. 22, 32.

Figure 1. Variance effect estimate accuracy and confidence interval coverage

Variance effect estimate accuracy (A, B) and 95% confidence interval coverage (C, D) of simulated genotypes with linear effect on outcome variance (A, C) or interaction effect (B, D). LAD-BF, least-absolute deviation regression Brown-Forsythe. OSCA-BF, original Brown-Forsythe test implemented in OSCA²⁶ including effect estimate derived from the test P-value²⁷. CI, confidence interval.

Figure 2. Effect of top gene-environment interaction loci on trait mean and variance

Per-allele effect of SNP stratified by modifier on outcome mean estimated with

heteroscedastic-consistent standard errors²⁹ and unstratified effect of SNP on variance

estimated using LAD-BF (genotype 0 vs 1 and 0 vs 2) with or without adjustment for the

interaction term. All estimates were adjusted for age, sex (except for rs1065853, rs1799941

and rs938555 on variance as the modifier was sex) and top ten genetic principal

components. SD, standard deviation. CI, confidence interval. ALT, alanine aminotransferase.

LDL, low-density lipoprotein. BMI, body mass index. Low BMI, <= 26.7 kg/m². High BMI, >

26.7 kg/m².

Per allele effect of SNP stratified by modifier on outcome mean estimated with heteroscedastic-consistent standard errors²⁹ and unstratified effect of SNP on variance estimated using LAD-BF (genotype 0 vs 1 and 0 vs 2) with or without adjustment for the interaction term. All estimates were adjusted for age, sex, and top ten genetic principal components. SD, standard deviation. CI, confidence interval. ALP, alkaline phosphatase. ALT, alanine aminotransferase. AST, aspartate aminotransferase. GGT, gamma glutamyltransferase.

Table 1. Simulation studies of the Brown-Forsythe test

700

Figure	Aim	Conditions
1	Determine variance effect estimate accuracy and confidence interval coverage	Increasing interaction effect size.
S2	Estimate power of variance tests to detect interaction effects using normal/non-normal outcomes	Increasing interaction effect size. Normal, log-normal, and t-distribution residuals
S3	Estimate type I error of variance tests with normal/non-normal outcomes	Increasing SNP minor allele frequency. Normal, log-normal, t-distribution, and mixed-normal residuals
S4	Adjusting for interaction effect on variance effect estimate	With/without adjustment for modifier and interaction term in first-stage model
S5	Estimate model runtime performance	Increasing number of CPU threads

SNP, single-nucleotide polymorphism. Log, natural logarithm. CPU, central processing unit.





